Specifications
- Purity
- ≥98% (HPLC)
- Appearance
- White to off-white powder
- Identity
- 1H-NMR
Properties
- Solvents
- Soluble in DMSO (20mg/ml).
Category: API's & Intermediates
Irbesartan is an orally available angiotensin II type 1 (AT1) receptor antagonist (IC50 = 1.3 nM) with antihypertensive activity. It binds to AT1 receptor with >5000 times higher affinity compared to AT2 receptor. Irbesartan also elicits selective peroxisome proliferator-activated receptor γ (PPARγ)-modulating activity and exhibits metabolic, anti-inflammatory and antioxidative properties. Irbesartan inhibits the receptor for advanced glycation end-products (RAGE)/high mobility group box 1 (HMGB1) axis and maybe useful in prevention and treatment of various diseases. Formulations containing irbesartan have been used, alone and in combination with diuretics, in the treatment of hypertension.
Synonyms | 2-Butyl-3-[[2?-(2H-tetrazol-5-yl)[1,1?-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one, Avapro, BMS-186295, SR-47436 |
---|---|
Purity | ≥98% (HPLC) |
Appearance | White to off-white powder |
CAS-Number | 138402-11-6 |
Molecular Formula | C25H28N6O |
Molecular Weight | 428.53 |
Identity | 1H-NMR |
Solvents | Soluble in DMSO (20mg/ml). |
Smiles | O=C1C2(CCCC2)N=C(CCCC)N1CC(C=C3)=CC=C3C4=CC=CC=C4C5=NN=NN5 |
InChi Key | YOSHYTLCDANDAN-UHFFFAOYSA-N |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | +4°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
Transportation | Not dangerous goods |
References | (1) L. Ruilope, J. Hypertens. Suppl. 15, S15 (1997) (Review), (2) M. Burnier, Circulation 103, 904 (2001), (3) A.H. Gradman, J. Human Hypert. 16, S9 (2002), (4) K. Kikuchi, et al., Int. J. Mol. Sci. 14, 18899 (2013) (Review), (5) Z.Z. Zhang, et al., J. Transl. Med. 11, 229 (2013), (6) I. Taguchi, et al., Hypertens. Res. 36, 608 (2013), (7) I.T. Abdel-Raheem, et al., Fundam. Clin. Pharmacol. 29, 286 (2015), (8) J. Zhong, et al., Int. Immunopharmacol. 42, 176 (2017), (9) I.A. Darwish, et al., Prof. Drug Subst. Excip. Rel. Meth. 46, 185 (2021) (Review) |
InChi | InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30) |
Quantity | 50 mg, 250 mg, Bulk |